Veracyte, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Marc A. Stapley
- Full Time Employees
- 824
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 6000 Shoreline Court South San Francisco CA United States of America 94080
- IPO Date
- Oct 30, 2013
- CIK
- 0001384101
- Website
- veracyte.com
- Similar Companies
- Business
- Veracyte, Inc. (Nasdaq: VCYT) is a global diagnostics company that develops and commercializes genomic tests to empower clinicians with precision insights for diagnosing and treating cancer, focusing on pivotal moments in patient care such as avoiding unnecessary surgery, selecting optimal therapies, and monitoring disease progression. The company offers a portfolio of molecular diagnostics through its Veracyte Diagnostics Platform, which leverages broad genomic assays, clinical data, AI-assisted analysis, and evidence generation; core products include the Afirma Genomic Sequencing Classifier and Xpression Atlas for thyroid cancer to reduce unnecessary surgeries; Decipher Prostate Genomic Classifier for localized and metastatic prostate cancer treatment decisions; Decipher Bladder Genomic Classifier for bladder cancer molecular subtyping; Prosigna Breast Cancer Assay for early-stage breast cancer prognosis; Percepta Nasal Swab Test for noninvasive lung cancer risk assessment in CT-detected nodules; and the nCounter analysis system services for decentralized testing. These tests are processed primarily through the company's CLIA-certified laboratories in South San Francisco and San Diego, California, and Austin, Texas, with IVD versions enabling global expansion beyond the United States. Founded in 2006 and headquartered in South San Francisco, California, Veracyte operates in the healthcare sector, specifically biotechnology and diagnostics, serving oncologists, urologists, endocrinologists, surgeons, and pulmonologists across the cancer care continuum. The company targets patients with high-prevalence cancers including thyroid, prostate, bladder, breast, lung, and kidney, generating revenue from testing services, product sales such as Prosigna kits, and biopharmaceutical collaborations. In recent developments, Veracyte completed the acquisition of C2i Genomics in early 2024 for $70 million in stock plus up to $25 million in milestones, integrating whole-genome minimal residual disease (MRD) technology to expand into treatment monitoring and recurrence detection, with the first TrueMRD test for muscle-invasive bladder cancer slated for commercial launch in the first half of 2026. The company launched limited access to Decipher Prostate for metastatic patients in early 2025, broadening its coverage across the prostate cancer risk spectrum, and entered a partnership with Helix to bundle whole exome hereditary cancer testing with Decipher for enhanced therapeutic guidance per NCCN guidelines. Veracyte also reported strong Q3 2025 financial results with 14% revenue growth to $131.9 million, raised its full-year 2025 revenue outlook to $510 million, and advanced its pipeline including Prosigna LDT launch in mid-2026 while achieving 30% adjusted EBITDA margins.
Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term
Here's Why Veracyte (VCYT) is a Strong Growth Stock
State Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio?
Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report?
Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer Transcript
Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer
ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte's Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy
Veracyte: The Evidence Flywheel Is Turning Into A Cash Flow Platform
Is it Worth Retaining Veracyte Stock in Your Portfolio for Now?
Veracyte genomic test identifies breast cancer patients who can skip chemo
Veracyte Stock Surges 65.8% in a Year: What's Driving the Rally?
Here's Why Veracyte (VCYT) is a Strong Momentum Stock
Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer
Veracyte to Participate in Upcoming Investor Conferences
Why Veracyte (VCYT) is a Top Growth Stock for the Long-Term
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer